Aldeyra Therapeutics, Inc. (ALDX)
Fuera de horario:
Aldeyra Therapeutics, Inc.
131 Hartwell Avenue
Suite 320
Lexington, MA 02421
United States
781 761 4904
https://www.aldeyra.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 10
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Todd C. Brady M.D., Ph.D. | CEO, President & Director | 834.1k | N/D | 1972 |
| Dr. Stephen G. Machatha Ph.D. | Chief Development Officer | 503.62k | N/D | 1977 |
| Mr. Kelly Mizer | Vice President of Commercial Strategy & Operations | N/D | N/D | N/D |
| David Burke | Head of Investor Relations | N/D | N/D | N/D |
Descripción
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss. In addition, it develops ADX-246 in systemic immune-mediated disease; and ADX-248 in geographic atrophy. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
Gestión corporativa
La calificación ISS Governance QuickScore de Aldeyra Therapeutics, Inc. a partir del 1 de abril de 2024 es 8. Las puntuaciones principales son Auditoría: 8; Junta: 9; Derechos del accionista: 8; Compensación: 6.
